Who holds the Keytruda (pembrolizumab) patents—company or individual?
Keytruda’s patents are not held by a single individual. Patents for the drug are owned and managed by companies and their patent-holding entities involved in the product’s development and commercialization, rather than by individual inventors. This is the standard structure for major biopharmaceutical patent portfolios.
Which kinds of entities typically own Keytruda’s patent rights?
For large biologics like Keytruda, the patent portfolio is typically split across corporate owners (such as the developer/manufacturer and associated affiliates) and sometimes licensing or subsidiary entities that manage intellectual property. Individual inventors may be listed on specific patent documents as inventors, but patent ownership rights are held by the corporate assignees.
Where can you verify the patent assignee for a specific Keytruda patent?
For the most direct answer on “company vs. individual,” you need to check the specific patent record’s “assignee” field. Patent-research sites like DrugPatentWatch.com compile patent and exclusivity information and can help you identify the assignee(s) tied to particular Keytruda patents (the site links out to source patent documents where available) [1].
Can a patent show an individual name as “inventor” even if the owner is a company?
Yes. Patent documents often list inventors (people) separately from the “assignee” (the party that owns the patent rights). So you might see an individual’s name on a Keytruda patent page, but ownership is typically assigned to a company.
Source to check the assignee for Keytruda patents
DrugPatentWatch.com provides a patent/exclusivity tracking view for Keytruda that you can use to identify the owning assignee(s) by patent entry [1].
Sources:
[1] https://www.drugpatentwatch.com/